Recent research has opened up new treatment options for men with advanced prostate cancer. Providence Cancer Institute offers three new clinical trials investigating targeted therapies, immunotherapy, and oral bioavailable chemotherapy for men with metastatic castration-resistant prostate cancer (mCRPC):
Talazoparib plus Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)
TALAPRO-2 is a phase III, randomized, double-blind study to evaluate the safety and effectiveness of talazoparib (Talzenna), a PARP inhibitor approved for certain breast cancers, when given with standard care enzalutamide (Xtandi), an antiandrogen therapy, compared to enzalutamide with placebo. Talazoparib is under investigation as an experimental therapy for several types of cancer, and the preliminary results of this study showed promising findings in mCRPC. Men with mCRPC with and without DNA repair defects are eligible.
REGN5678 with Cemiplimab in patients with mCRPC
This is a phase I/II, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability and effectiveness of REGN5678, an experimental bispecific antibody targeting CD28 and PSMA, given with cemiplimab (Libtayo), a PD-1 checkpoint inhibitor approved for certain skin cancers. Preclinical studies demonstrated anticancer activity of bispecific antibodies in prostate cancer.
ModraDoc006/r vs. Docetaxel IV in Patients with mCRPC Suitable for Taxane Therapy
This phase IIb, randomized, multicenter study evaluates the safety and tolerability of ModraDoc006, an experimental oral therapeutic based on docetaxel (Taxotere), a standard taxane chemotherapy, when given with ritonavir (Norvir), a protease inhibitor, compared to intravenous docetaxel monotherapy. A prior study showed encouraging anticancer activity and increased absorption of ModraDoc006 when given with ritonavir.
Referrals and more studies
Providence Cancer Institute currently offers ten clinical trials focused on genitourinary cancers; see all genitourinary studies. New studies are added frequently. For a complete list of studies in all cancer types, please visit our website.
For more information about these studies, or to enroll a patient, please call our Clinical Research office at 503-215-2614 or submit a referral form.
A team of prostate cancer specialists
Medical oncologist Brendan Curti, M.D., is the principal investigator on all three of these studies. Dr. Curti is Franz Chair of Clinical Research and director of genitourinary oncology research at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center.
Our team includes oncologists who specialize in genitourinary cancers, as well as prostate-cancer-focused research nurses, laboratory scientists, data coordinators, and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for men with prostate cancer.
About the AuthorMore Content by Providence News Team